The landscape of technological devices is changing at an unprecedented pace from having limited access to CGM and poor awareness of insulin pump therapy only a few years ago to today where there is an unprecedented expansion in access to CGM and the dawn of Hybrid closed-loop ‘artificial pancreas’ systems.

 

To keep up to date with this fast pace, a new initiative Diabetes Technology Network (Ireland), was launched by Consultant Endocrinologists Hannah Forde (Beaumont Hospital, Dublin) and Tomás Griffin (University Hospital Galway) and supported by Diabetes Ireland.

 

The long-term goal is to make diabetes technology accessible for all people who need it to manage diabetes in Ireland and to have ongoing support from your local diabetes team.

 

To achieve this, DTN Ireland looks to raise awareness, inform and educate people with diabetes about the benefits of diabetes technology and encourage diabetes specialists to provide access to technology through their clinics.

 

Diabetes Technology Network Ireland essentially aims to:

  • be the voice and advocate for better diabetes technology utilisation and uptake for people living with diabetes in Ireland and working with the relevant stakeholders to increase access to technologies in Ireland;
  • learn from the best international guidance and expertise and share best practices with diabetes specialists across the country through guidance documents/pathways on diabetes technology development;
  • support healthcare professionals in the delivery of technologies designed to improve the lives of people living with diabetes and their families, by delivering practical education to healthcare professionals on diabetes technology utilisation.

Since 2025, Diabetes Technology Network (Ireland) and Diabetes Ireland have been hosting

 

A series of meetings nationwide so people living with Type 1 diabetes and parents/carers of children with Type 1 diabetes can:

  • learn about the benefits of diabetes technology and how it will enable them to manage their condition more effectively,
  • learn about the various technologies currently available in Ireland and their benefits,
  • be able to physically see, touch and feel the technology and
  • learn about the latest research developments in managing Type 1 diabetes.

We aim for these meetings to equip attendees with the knowledge to make informed decisions, in collaboration with their diabetes care team, about the technology that best addresses their clinical needs and aligns with their lifestyle.

  • In 2025, meetings took place in Galway, Cork, Letterkenny, and Dublin.
  • In 2026, we plan to hold sessions in Dundalk, Kerry, and Waterford.

DTN IRL is supported by

Abbott Novo Nordisk
Dexcom Medtronic Air Liquide
Back to top